Asahi Kasei Therapeutics gets FDA approval for HOVILPRI
Asahi Kasei Therapeutics said it secured U.S. FDA approval for HOVILPRI (pritelivir) 100 mg tablets to treat drug-resistant HSV in immunocompromised adults.
Asahi Kasei Therapeutics said it secured U.S. FDA approval for HOVILPRI (pritelivir) 100 mg tablets to treat drug-resistant HSV in immunocompromised adults.